Literature DB >> 17717191

Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA.

Maciej Gasior1, Natalie A White, Michael A Rogawski.   

Abstract

Convection-enhanced delivery (CED) permits the homogeneous distribution of therapeutic agents throughout localized regions of the brain parenchyma without causing tissue damage as occurs with bolus injection. Here, we examined whether CED infusion of the N-type calcium channel antagonists omega-conotoxin GVIA (omega-CTX-G) and omega-conotoxin MVIIA (omega-CTX-M) can attenuate kindling measures in fully amygdala-kindled rats. Rats were implanted with a combination infusion cannula-stimulating electrode assembly into the right basolateral amygdala. Fully kindled animals received infusions of vehicle, omega-CTX-G (0.005, 0.05, and 0.5 nmol), omega-CTX-M (0.05, 0.15, and 0.5 nmol), proteolytically inactivated omega-CTX-M (0.5 nmol), or carbamazepine (500 nmol) into the stimulation site. CED of omega-CTX-G and omega-CTX-M over a 20-min period resulted in a dose-dependent increase in the afterdischarge threshold and a decrease in the afterdischarge duration and behavioral seizure score and duration during a period of 20 min to 1 week after the infusion, indicating an inhibitory effect on the triggering and expression of kindled seizures. The protective effects of omega-conotoxins reached a maximum at 48 h postinfusion, and then they gradually resolved over the next 5 days. In contrast, carbamazepine was active at 20 min but not at 24 h after the infusion, whereas CED of vehicle or inactivated omega-CTX-M had no effect. Except for transient tremor in some rats receiving the highest toxin doses, no adverse effects were observed. These results indicate that local CED of high-molecular-weight presynaptic N-type calcium channel blockers can produce long-lasting inhibition of brain excitability and that they may provide prolonged seizure protection in focal seizure disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717191      PMCID: PMC2257985          DOI: 10.1124/jpet.107.125047

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion.

Authors:  Russell R Lonser; Stuart Walbridge; Kayhan Garmestani; John A Butman; Hugh A Walters; Alexander O Vortmeyer; Paul F Morrison; Martin W Brechbiel; Edward H Oldfield
Journal:  J Neurosurg       Date:  2002-10       Impact factor: 5.115

2.  Omega-conotoxin GVIA blocks synaptic transmission in the CA1 field of the hippocampus.

Authors:  P Dutar; O Rascol; Y Lamour
Journal:  Eur J Pharmacol       Date:  1989-12-19       Impact factor: 4.432

Review 3.  Current treatments of epilepsy.

Authors:  Siddhartha Nadkarni; Josiane LaJoie; Orrin Devinsky
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

4.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  Omega-conotoxin MVIIC reversibly inhibits a human N-type calcium channel and calcium influx into chick synaptosomes.

Authors:  C J Grantham; D Bowman; C P Bath; D C Bell; D Bleakman
Journal:  Neuropharmacology       Date:  1994-02       Impact factor: 5.250

6.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

7.  Peptide neurotoxins from fish-hunting cone snails.

Authors:  B M Olivera; W R Gray; R Zeikus; J M McIntosh; J Varga; J Rivier; V de Santos; L J Cruz
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

Review 8.  Focal treatment for refractory epilepsy: hope for the future?

Authors:  Karen E Nilsen; Hannah R Cock
Journal:  Brain Res Brain Res Rev       Date:  2004-03

9.  A pharmacological study in the kindling model of epilepsy.

Authors:  T E Albertson; R M Joy; L G Stark
Journal:  Neuropharmacology       Date:  1984-10       Impact factor: 5.250

10.  Determination of disulfide bridge pattern in omega-conopeptides.

Authors:  D Chung; S Gaur; J R Bell; J Ramachandran; L Nadasdi
Journal:  Int J Pept Protein Res       Date:  1995 Sep-Oct
View more
  12 in total

1.  Pro- and Anticonvulsant Effects of the Ant Dinoponera quadriceps (Kempf) Venom in Mice.

Authors:  D A M F Nôga; F C Cagni; J R Santos; D Silva; D L O Azevedo; A Araújo; R H Silva; A M Ribeiro
Journal:  Neotrop Entomol       Date:  2015-06-05       Impact factor: 1.434

Review 2.  Therapeutic devices for epilepsy.

Authors:  Robert S Fisher
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

3.  Convection-enhanced delivery of botulinum toxin serotype A into the nonhuman primate cisterna magna and hippocampus.

Authors:  Davis P Argersinger; Stuart Walbridge; Nicholas M Wetjen; Alexander O Vortmeyer; Tianxia Wu; John A Butman; John D Heiss
Journal:  J Neurosurg       Date:  2019-07-19       Impact factor: 5.115

Review 4.  Convection-enhanced delivery for the treatment of brain tumors.

Authors:  Waldemar Debinski; Stephen B Tatter
Journal:  Expert Rev Neurother       Date:  2009-10       Impact factor: 4.618

Review 5.  Advances in the application of technology to epilepsy: the CIMIT/NIO Epilepsy Innovation Summit.

Authors:  Steven C Schachter; John Guttag; Steven J Schiff; Donald L Schomer
Journal:  Epilepsy Behav       Date:  2009-09       Impact factor: 2.937

6.  Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.

Authors:  Maciej Gasior; Rebecca Tang; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2013-06-14       Impact factor: 4.030

Review 7.  Convection-enhanced delivery in the treatment of epilepsy.

Authors:  Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 8.  Nanotechnology for delivery of drugs to the brain for epilepsy.

Authors:  Margaret F Bennewitz; W Mark Saltzman
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

9.  Evolution and prospects for intracranial pharmacotherapy for refractory epilepsies: the subdural hybrid neuroprosthesis.

Authors:  Nandor Ludvig; Geza Medveczky; Jacqueline A French; Chad Carlson; Orrin Devinsky; Ruben I Kuzniecky
Journal:  Epilepsy Res Treat       Date:  2010-02-08

Review 10.  Conotoxins that confer therapeutic possibilities.

Authors:  Magbubah Essack; Vladimir B Bajic; John A C Archer
Journal:  Mar Drugs       Date:  2012-06-04       Impact factor: 6.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.